BridgeMD
New treatment option for Multiple Sclerosis, Relapsing-Remitting
Official title Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
ClinicalTrials.gov ID: NCT05958381
What this study is testing
- What it's testing
- The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve verbal retrieval in multiple sclerosis patients. The primary outcome measures are neuropsychological assessments of verbal retrieval, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- º Diagnosed with relapsing-remitting multiple sclerosis (RRMS)
- º Memory retrieval deficit based on neuropsychological testing done in our lab
- º Must be fluent in speaking and reading English.
You likely can't join if
- º Relapse or acute MS exacerbation or a course of steroids in the two months preceding the testing º Participants using benzodiazepines must have...
- dementia of any type
- epilepsy or other seizure disorders
- severe traumatic brain injury
- brain tumor
- present drug abuse
See the full eligibility criteria
- º Diagnosed with relapsing-remitting multiple sclerosis (RRMS)
- º Memory retrieval deficit based on neuropsychological testing done in our lab
- º Must be fluent in speaking and reading English.
- º Relapse or acute MS exacerbation or a course of steroids in the two months preceding the testing º Participants using benzodiazepines must have been on a stable dose for at least two months º Potentially confounding...
- dementia of any type
- epilepsy or other seizure disorders
- severe traumatic brain injury
- brain tumor
- present drug abuse
- stroke
- blood vessel abnormalities in the brain
- Parkinson's disease
- Huntington's disease º inability to give informed consent º cranial implants º skull defects that affect tDCS administration º use of medications that interact with or potentially interact with tDCS effects, including:
- anti-convulsants
- L-dopa
- carbamazepine
- sulpiride
- pergolide
- lorazepam
- rivastigmine
- dextromethorphan
- D-cycloserine
- flunarizine
- ropinirole
- stimulants (dextroamphetamine/amphetamine/modafinil/armodafinil) must be stopped during enrollment
The study team makes the final eligibility decision.
Where it's taking place
- Richardson, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Richardson, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.